Business Context and Reporting Period
This Form 8-K Current Report was filed by Collegium Pharmaceutical, Inc. on May 10, 2024, regarding events occurring on May 9, 2024. The filing addresses significant changes in the Company's executive leadership and Board of Directors composition.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to executive compensation: the Interim President and CEO will receive a base salary of $291,666 annually, which represents one-third of the departing CEO's current base salary.
Material Changes
- Executive Departure: Joseph Ciaffoni is stepping down as President and Chief Executive Officer effective May 24, 2024. His departure is classified as a termination without cause.
- Board Reduction: Mr. Ciaffoni will not stand for re-election at the Annual Meeting on May 16, 2024. Consequently, the Board size will decrease from nine to eight members immediately following the meeting.
- Leadership Appointment: Michael Heffernan, currently Chairman of the Board, has been appointed Interim President and Chief Executive Officer effective May 24, 2024.
Outlook, Risks, and Management Commentary
The Board has initiated a search for a permanent President and Chief Executive Officer. Mr. Heffernan will serve in the interim capacity until a new CEO commences employment or a date determined by the Board. The filing states there are no undisclosed arrangements or family relationships influencing Mr. Heffernan's selection. No specific risks, contingencies, or unusual items beyond the leadership transition are detailed in this report.
Investor Verification Checklist
- Verify the exact effective date of the leadership transition (May 24, 2024).
- Review the Company's proxy statement filed on April 5, 2024, for Michael Heffernan's full biography.
- Monitor upcoming announcements regarding the search for a permanent CEO.
- Confirm the impact of the Board size reduction on corporate governance policies.